Vaccinia Capping Enzyme, GMP-Grade (GMP-VCS-VE101), DMF #038028, Accession:

/在： /通过：
  • 产品概述
  • 产品规格
  • 运输及存储
  • 品牌声明

    • 产品概述

    产品描述

    The 7-methylguanosine cap structure (m7Gppp, Cap0) is a specific feature in eukaryotic mRNA, which is required for mRNA stability, splicing, nuclear export, effective translation, and mRNA decay. Vaccinia Capping Enzyme, a heterodimer of D1 and D12 subunits, adding the Cap0 structure to the 5′ end of the RNA. The D1 subunit comprises an N-terminal RNA triphosphatase (TPase), a guanylyltransferase (GTase), and a C-terminal guanine-N7-methyltransferase (MTase). The D12 subunit binds and stimulates the MTase. NOTE: mRNA Cap 2′-O-Methyltransferase (ChemWhat #GMP-MEH-VE101) is required to generate Cap 1 structure that reduces cellular innate immune response when the RNA is used in vivo . This product has been filed with the FDA Drug Master Files (DMF) and is assigned DMF #038028.

    Biotinylated

    产品规格

    靶点

    分子别名

    Accession

    种属

    蛋白序列

    分子量

    活性

    产品标签

    表达系统

    纯度

    内毒素

    运输及存储

    产品外观

    Liquid

    运输条件

    Shipped with blue ice

    制剂

    复溶

    存储和稳定性

    -20±5°C for 24 months. Avoid repeated freeze-thaw cycles.

    该产品的品牌ChemWhat是Watson的注册商标，由Watson授权江苏沃尔森在中国大陆地区使用，ChemWhat官方网址.